Evaluation of effect of nilotinib in an experimental corneal neovascularization model

Authors : Hakan YILDIRIM, Mehmet BALBABA, Murat ERDAĞ, Mehmet CANLEBLEBİCİ, Ali DAL, Nevin İLHAN, Yesari ERÖKSÜZ, Sabiha GÜNGÖR KOBAT

Pages : 431-437

Doi:10.38053/acmj.1175479

View : 32 | Download : 8

Publication Date : 2022-10-22

Article Type : Research Paper

Abstract :Aim: This study aims to investigate the neovascularization-inhibiting effect of topical nilotinib and to determine the effective dose of nilotinib. Material and Method: In this study, 42 healthy Wistar albino rats were randomly divided into six groups. The left corneas of all rats except group 1 were cauterized with silver nitrate. Group 1 was the healthy control, with no corneal vascularization, which did not receive any treatment; Group 2 (sham) did not receive treatment, only topical DMSO; Groups 3, 4, and 5 received topical nilotinib at doses of 10, 20, and 40 μM three times a day, respectively; Group 6 received 5 mg/dL topical bevacizumab three times for a day for seven days. On the 8th day, photographs of the corneas were taken, and the percentage of corneal neovascularization area was calculated. Following all rats being killed via anesthesia, the corneas were removed to determine the levels of vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) ELISA and corneal immune staining. Results: Other than Group 3, the percentage of neovascular corneal area was lower in the treatment groups compared to Group 2 (p<0.05). The intensity of VEGF and PDGF immune staining was also lower in the treatment groups. The treatment groups showed no significant differences compared to Group 1, except Group 3. The VEGF ELISA levels were statistically significantly lower in the treatment groups compared to Group 2 (p<0.05), with the exception of Group 3. The PDGF ELISA levels were statistically significantly lower in the treatment groups compared to Group 2 (p<0.05), and the Group 4 PDGF levels were statistically the lowest among the treatment groups. Conclusion: Nilotinib was as effective as bevacizumab in the regression of corneal neovascularization. We observed that nilotinib was effective at doses of 20 μM and more.
Keywords : Corneal neovascularization, nilotinib, bevacizumab, VEGF, PDGF